Dossier assessment
Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Report documents
-
Dossier assessment
Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Additional information
Federal Joint Committee (G-BA)
2021-03-04: A G-BA decision was published.
Project details
- Project no.
- G20-22
- Commission
- Commission awarded on 16.09.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Haematology
- Note
-
In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. The resolution on the extent of added benefit is passed by the G-BA after the hearing. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA Website.
Connected Projects
-
Addendum
Belantamab mafodotin (multiple myeloma) - Addendum to Commission G20-22
Status: Commission completed
-
Dossier assessment
Belantamab mafodotin (multiple myeloma; combination with pomalidomide and dexamethasone) – Benefit assessment according to §35a Social Code Book V35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Belantamab mafodotin (multiple myeloma; combination with bortezomib and dexamethasone) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed